千金药业品牌怎么样 申请店铺

我要投票 千金药业在女性洗液行业中的票数:639 更新时间:2025-12-14
千金药业是哪个国家的品牌?「千金药业」是 株洲千金药业股份有限公司 旗下著名品牌。该品牌发源于湖南省株洲市,由创始人江端预在1993年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力千金药业品牌出海!将品牌入驻外推网,定制千金药业品牌推广信息,可以显著提高千金药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

千金药业怎么样

株洲千金药业股份有限公司,前身为株洲市中药厂,1993年进行股份制改造,2004年上市(股票代码:600479),千金药业系国家大中型中药制药企业。旗下拥有十三家控股子公司。

千金药业注册资本3.05亿元,2013年底,总资产达到18.88亿元。经济效益综合指标在湖南省医药行业同行中排名第一,位居国内中药行业前列。

公司拥有国内最大、工艺最成熟的中药片剂生产线,日产量为1200万片,年产量可达35亿片。硬件装备先进,达到国内领先水平。2009年12月,位于河西天元区栗雨工业园的千金女性健康产业基地正式投产,该基地建设属国家高新技术产业项目,占地200亩达产规模30亿元。

公司专注于女性健康产业,已形成女性健康系列产品。公司现有片剂、颗粒剂、硬胶囊剂等八个剂型,十三条生产线,全部通过GMP认证。主要产品有:妇科千金片(胶囊)、补血益母颗粒、养阴清肺糖浆、千金椿乳凝胶、痛经宁糖浆(胶囊)、乳癖康胶囊妇科调经片、千金宁洗液、千金止带丸、八珍益母片、加味逍遥丸、乳泉颗粒等。

公司现有14个独家产品,近50个生产批文,拥有各项专利206件。其中主导产品妇科千金片(胶囊)是国家中药保护品种、国家基本药物,国家医保目录甲类品种,《中国药典》收载品种,国家秘密技术项目,是唯一列入国家秘密技术的妇科中成药品种。

千金药业及下属子公司现有员工4000余人,其中总部员工1800余人,大专以上学历人员超过52%,平均年龄为29岁,在职职业药师40余名。公司建立了近千人的专业化特质营销队伍,在全国除西藏、台湾、香港、澳门外的30多个省市设有联络处。

公司“十二五”战略目标是:成为女性健康领域标杆企业,成为中药衍生领域品牌产品;实现集团公司年销售收入达40亿元;实现员工收入增长翻番;使千金药业成为“快乐千金”、“和谐千金”、“富裕千金”和“品牌千金”。

发展历程

▲1966年:在株洲市徐家桥永安仁药店后,株洲千金药业股份有限公司的前身——株洲市中药加工厂(即株洲市医药公司星火中成药加工厂)成立。生产参苏丸、五积散等产品;注册商标为“火炬”。

▲1968年:更名为株洲市六二六制药厂,开始生产町水糖浆剂、丸剂和片剂。

▲1973年:六二六制药厂搬迁到金钩山路的原市委党校校址。

▲1975年:更名为株洲市中药制药厂。

▲1976年:启动“妇科千金片”研制。

▲1979年:注册使用“牡丹”商标;同年,妇科千金片获得生产批文并开始试生产。

▲1981年:被株洲市政府列为关、停、并、转的对象;同年,妇科千金片消毒灭菌技术攻关获得成功。

▲1983年:“妇科千金片”被评为湖南省优质产品。

▲1984年:牡丹牌“脑乐静”被评为湖南省优质产品。

▲1985年:“妇科千金片”被国家医药管理局评为优质产品。

▲1987年:更名为株洲市中药厂。

▲1991年:妇科千金片荣获国优银质奖。

▲1993年:改组为株洲千金药业股份有限公司;同年,妇科千金片销往新加坡。

▲1994年:妇科千金片入选国家基本药物。

▲1995年:“千金”牌商标获国家工商局注册商标证书。

▲1996年:“妇科千金片”被认定为1995年度湖南名牌产品。

▲1998年:成立陇西药材分公司。同年,湘江药业股份有限公司成立,千金药业投资816万元,占总股本的51%。同年,株洲千金医药贸易有限公司成立,注册资本500万元,千金药业和湘江药业分别投资480万元和20万元。

Zhuzhou Qianjin Pharmaceutical Co., Ltd., formerly Zhuzhou traditional Chinese medicine factory, was transformed into a joint-stock company in 1993 and listed in 2004 (Stock Code: 600479). Qianjin pharmaceutical is a large and medium-sized national traditional Chinese medicine pharmaceutical enterprise. It has 13 holding subsidiaries. Qianjin pharmaceutical has a registered capital of 305 million yuan, and by the end of 2013, its total assets reached 1888 million yuan. The comprehensive index of economic benefit ranks the first among the medical industry peers in Hunan Province, and ranks in the forefront of the domestic traditional Chinese medicine industry. The company has the largest and most mature production line of traditional Chinese medicine tablets in China, with a daily output of 12 million tablets and an annual output of 3.5 billion tablets. The hardware equipment is advanced, reaching the leading level in China. In December 2009, the Qianjin women's health industrial base, located in Liyu Industrial Park, Tianyuan District, Hexi, was officially put into operation. The construction of the base is a national high-tech industrial project, covering an area of 200 mu and reaching a production scale of 3 billion yuan. The company focuses on women's health industry and has formed a series of women's health products. The company has eight dosage forms such as tablet, granule, hard capsule and thirteen production lines, all of which have passed GMP certification. The main products are: gynecological Qianjin tablets (capsules), blood enriching mother granule, Yangyin Qingfei syrup, Qianjin Chun milk gel, dysmenorrhea syrup (capsule), Rupikang capsule, gynecological regulating menstruation tablets, Qianjin Ning lotion, Qianjin Zhibao pills, eight Zhen Yi Mu tablets, Jiawei Xiaoyao pills, and Ruquan granules. The company has 14 exclusive products, nearly 50 production approvals and 206 patents. Among them, the leading product Fukeqianjin tablet (capsule) is the national traditional Chinese medicine protection variety, the national basic drug, the category a variety in the national medical insurance catalog, the variety included in the Chinese Pharmacopoeia, and the national secret technology project. It is the only variety of Chinese traditional medicine for gynecology listed in the national secret technology. Qianjin Pharmaceutical Co., Ltd. and its subsidiaries have more than 4000 employees, including more than 1800 employees in the headquarters, more than 52% of them with college degree or above, with an average age of 29 and more than 40 on-the-job professional pharmacists. The company has established a professional marketing team of nearly one thousand people, with liaison offices in more than 30 provinces and cities except Tibet, Taiwan, Hong Kong and Macao. The company's "12th Five Year Plan" strategic goal is: to become a benchmark enterprise in the field of women's health and a brand product in the field of traditional Chinese medicine derivatives; to realize the annual sales revenue of the group company reaching 4 billion yuan; to realize the doubling of the income growth of employees; to make Qianjin pharmaceutical industry become "happy Qianjin", "harmonious Qianjin", "rich Qianjin" and "brand Qianjin". Development history ▲ 1966: after xujiaqiao yong'anren drugstore in Zhuzhou City, Zhuzhou Qianjin Pharmaceutical Co., Ltd., the predecessor of Zhuzhou traditional Chinese medicine processing factory (i.e. Xinghuo traditional Chinese medicine processing factory of Zhuzhou pharmaceutical company), was established. Production of Shensu pill, Wuji powder and other products; the registered trademark is "Torch". In 1968, it was renamed Zhuzhou 626 pharmaceutical factory and began to produce machishui syrup, pills and tablets. ▲ 1973: the 626 pharmaceutical factory was moved to the original site of the Party School of the municipal Party committee of jinyushan road. ▲ 1975: renamed Zhuzhou traditional Chinese medicine pharmaceutical factory. ▲ 1976: launch the development of "gynecology Qianjin tablet". In 1979, "Peony" trademark was registered and used; in the same year, gynecology Qianjin tablet obtained production approval and began trial production. In 1981, it was listed by Zhuzhou municipal government as the target of "close, stop, merge and transfer"; in the same year, the disinfection and sterilization technology of gynecology Qianjin tablet was successfully tackled. ▲ in 1983, "gynecology Qianjin tablet" was rated as high quality product of Hunan Province. ▲ 1984: Peony brand "Naolejing" was rated as high quality product of Hunan Province. In 1985, "gynecology Qianjin tablet" was rated as a high-quality product by the State Administration of medicine. ▲ 1987: renamed Zhuzhou traditional Chinese medicine factory. ▲ 1991: Gynecology Qianjin tablet won the national excellent silver medal. In 1993, it was reorganized into Zhuzhou Qianjin Pharmaceutical Co., Ltd. in the same year, Qianjin tablets for gynecology were sold to Singapore. ▲ 1994: Gynecology Qianjin tablet was selected as the national basic drug. ▲ in 1995, "Qianjin" brand trademark obtained the registered trademark certificate of the State Administration for Industry and commerce. In 1996, "gynecology Qianjin tablet" was recognized as the famous brand product of Hunan in 1995. ▲ 1998: Longxi herbal medicine branch was established. In the same year, Xiangjiang Pharmaceutical Co., Ltd. was established. Qianjin pharmaceutical invested 8.16 million yuan, accounting for 51% of the total share capital. In the same year, Zhuzhou Qianjin Pharmaceutical Trading Co., Ltd. was established with a registered capital of 5 million yuan. Qianjin pharmaceutical and Xiangjiang pharmaceutical invested 4.8 million yuan and 200000 yuan respectively.

本文链接: https://brand.waitui.com/db288be38.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2025年人工智能核心产业规模有望破万亿元

12月14日,从中国信息通信研究院了解到,今年以来,我国人工智能产业呈加速发展态势,2025年人工智能核心产业规模有望突破万亿元。数据显示,今年以来,生产制造环节的大模型应用增长显著,应用案例占比由去年的19.9%增长至25.9%,带动人工智能产业规模快速增长。(央视新闻)

3分钟前

近一周逾260家公司获机构调研 中科曙光和海光信息获调研数最多

近一周获得机构调研的个股有260多只,中科曙光和海光信息调研机构数最多。中科曙光和海光信息近一周有341家机构调研。中科曙光方面表示,尽管重组终止,但海光与曙光仍将在保持上市公司独立性基础上深化协同。安克创新、伟创电气等个股也均获得逾百家机构调研。从市场表现来看,近一周机构调研股月内平均上涨近1%。超捷股份、霍莱沃、斯瑞新材、博盈特焊、华菱线缆等个股均涨逾20%。(人民财讯)

3分钟前

调查:美联储明年1月降息25个基点的概率为24.4%

12月14日,据CME“美联储观察”:美联储2026年1月降息25个基点的概率为24.4%,维持利率不变的概率为75.69%。美联储到明年3月累计降息25个基点的概率为41.4%,维持利率不变的概率为50.5%,累计降息50个基点的概率为8.1%。(界面新闻)

3分钟前

万科三个展期议案均未获通过 仍有5个工作日宽限期

12月13日公告显示,万科“22万科MTN004”持有人会议三项展期议案均未获有效通过,核心展期规则均为展期一年且期间不付本息,差异在增信安排。议案一未设增信,无人同意;议案二增信加调整本息兑付,获83.40%同意;议案三仅一票同意。万科还有5个工作日宽限期谈判。(新浪财经)

3分钟前

2030年我国天然气产量将达3000亿立方米

《中国油气行业“十四五”发展成就报告》显示,中国正加速迈向现代油气产业发展新阶段,能源结构日趋多元均衡,2030年我国天然气产量将达到3000亿立方米。报告显示,“十四五”期间我国累计新增探明地质储量石油70亿吨、天然气7万亿立方米,分别较“十三五”增长约43%、40%,油气产量创历史新高。(央视新闻)

3分钟前

本页详细列出关于千金药业的品牌信息,含品牌所属公司介绍,千金药业所处行业的品牌地位及优势。
咨询